[PDF][PDF] HIV rebound is predominantly fueled by genetically identical viral expansions from diverse reservoirs

MA De Scheerder, B Vrancken, S Dellicour, T Schlub… - Cell host & …, 2019 - cell.com
Viral rebound upon stopping combined antiretroviral therapy poses a major barrier toward
an HIV cure. Cellular and anatomical sources responsible for reinitiating viral replication …

Increased levels of systemic LPS-positive bacterial extracellular vesicles in patients with intestinal barrier dysfunction

J Tulkens, G Vergauwen, J Van Deun, E Geeurickx… - Gut, 2020 - gut.bmj.com
We read with interest recent papers reporting on the impact of gut microbiota on several
aspects of health and disease due to altered intestinal permeability resulting in systemic …

[HTML][HTML] Evaluation of humoral and cellular responses in SARS-CoV-2 mRNA vaccinated immunocompromised patients

M Oyaert, MA De Scheerder, S Van Herrewege… - Frontiers in …, 2022 - frontiersin.org
Background Immunocompromised patients are at increased risk of severe COVID-19 and
impaired vaccine response. In this observational prospective study, we evaluated …

Robust sequential biophysical fractionation of blood plasma to study variations in the biomolecular landscape of systemically circulating extracellular vesicles across …

G Vergauwen, J Tulkens, C Pinheiro… - Journal of …, 2021 - Wiley Online Library
Separating extracellular vesicles (EV) from blood plasma is challenging and complicates
their biological understanding and biomarker development. In this study, we fractionate …

Benefits of antiretroviral therapy initiation during acute HIV infection

J De Clercq, S Rutsaert, MA De Scheerder… - Acta Clinica …, 2022 - Taylor & Francis
Objectives: In the last decade, there has been increasing scientific and legislative focus on
antiretroviral treatment (ART) for all people living with HIV. Especially early ART initiation …

Rapid viral rebound after analytical treatment interruption in patients with very small HIV reservoir and minimal on‐going viral transcription

P Pannus, S Rutsaert, S De Wit… - Journal of the …, 2020 - Wiley Online Library
Introduction Viral remission after analytical treatment interruption (ATI), termed post‐
treatment control, has been described in a small proportion of HIV‐positive patients. This …

[HTML][HTML] Efficacy and safety of camostat mesylate in early COVID-19 disease in an ambulatory setting: a randomized placebo-controlled phase II trial

E Tobback, S Degroote, S Buysse, L Delesie… - International Journal of …, 2022 - Elsevier
Objectives This study aimed to assess the efficacy and safety of 300 mg camostat mesylate
three times daily in a fasted state to treat early phase COVID-19 in an ambulatory setting …

[HTML][HTML] In-depth validation of total HIV-1 DNA assays for quantification of various HIV-1 subtypes

S Rutsaert, W De Spiegelaere, C Van Hecke… - Scientific reports, 2018 - nature.com
HIV-1 DNA quantification serves as an important reservoir biomarker in HIV cure trials.
However, the high genetic diversity of HIV-1 represented by different subtypes may bring …

Efficacy, durability, and tolerability of dolutegravir/lamivudine and dolutegravir/rilpivirine for the treatment of HIV in a real‐world setting in Belgium

R Nasreddine, JC Yombi, G Darcis, E Florence… - HIV …, 2023 - Wiley Online Library
Objectives A paradigm shift from three‐drug regimens to two‐drug regimens (2DRs) is
currently taking place in real‐world clinical practice. This study aimed to describe the …

[HTML][HTML] Motivations, barriers and experiences of participants in an HIV reservoir trial

MA De Scheerder, WPH van Bilsen, M Dullaers… - Journal of Virus …, 2021 - Elsevier
Objectives We aimed to investigate the motives, barriers and experiences of HIV-STAR
study participants. The HIV-STAR study was an analytical HIV treatment interruption trial …